Roche ' s Kadcyla nabs adjuvant treatment indication

The data found that Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news